A subgroup analysis of the OlympiAD trial involving Asian patients with BRCA germline pathogenic variants and HER2-negative metastatic BC reported that the patients treated with PARPi (olaparib) had a longer median progression-free survival than those receiving chemotherapy (5·7 months vs. 4·2 months; hazard ratio [HR] = 0·53) (45). Here, ERBB2 is linked to breast cancer.